Free US stock valuation multiples and PEG ratio analysis to identify reasonably priced growth companies with attractive risk-reward profiles. Our valuation framework helps you find stocks with the right balance of growth and value characteristics for your portfolio. We provide P/E analysis, PEG ratios, and relative valuation metrics for comprehensive valuation coverage. Find value in growth with our comprehensive valuation analysis and multiples tools for growth at a reasonable price strategies.
As of 2026-04-08, Immatics N.V. Ordinary Shares (IMTX) trades at a current price of $10.32, marking a 0.68% gain in recent trading. This analysis examines key technical levels, prevailing market context, and potential short-term price scenarios for the clinical-stage biotech firm, which focuses on developing novel cancer immunotherapies. No recent earnings data is available for IMTX at the time of writing, so technical price action and sector trends offer the most visible context for market part
What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68% - High Reward Trade
IMTX - Stock Analysis
3447 Comments
1802 Likes
1
Lowry
Experienced Member
2 hours ago
This feels like knowledge I shouldn’t have.
👍 51
Reply
2
Gerardine
Experienced Member
5 hours ago
Execution at its finest.
👍 105
Reply
3
Wykeem
Loyal User
1 day ago
I’m taking notes, just in case. 📝
👍 76
Reply
4
Karicia
Regular Reader
1 day ago
I read this and now I hear background music.
👍 267
Reply
5
Jozlynn
Returning User
2 days ago
Active rotation between sectors highlights the ongoing need for careful stock selection and diversification.
👍 44
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.